Table 2.
Characteristics of the 27 bladder cancer-related genes in the study.
| Gene Descriptor | References | ||
|---|---|---|---|
| Prognosis | Target Therapy | ||
| AKT1 | AKT serine/threonine kinase 1 | [27,28] | [29,30,31,32] |
| ANXA10 | Annexin A10 | [33,34] | |
| ARID1A | AT-Rich Interaction Domain 1A | [35,36,37,38,39] | |
| BIRC3 | Baculoviral IAP Repeat Containing 3 | [40,41] | |
| CCND1 | Cyclin D1 | [36,42] | |
| CCND3 | Cyclin D3 | [36,43] | |
| CDKN1A | Cyclin-dependent kinase inhibitor 1A (p21) | [27,44] | [44,45] |
| CDKN1B | Cyclin-dependent kinase inhibitor 1B (p27, Kip1) | [46,47] | |
| CDKN2A | Cyclin Dependent Kinase Inhibitor 2 (p16) | [27,38,48] | [48] |
| DAB2 | Disabled homolog 2 | [34,49] | [50] |
| EGFR | Epidermal growth factor receptor | [39,51,52] | [53] |
| FGF2 | Fibroblast growth factor 2 | [54,55] | |
| FGFR3 | Fibroblast growth factor receptor 3 | [19,27,36,37,39,56] | [53,57] |
| HRAS | HRas proto-oncogene, GTPase | [27,36,58] | [59] |
| HYAL2 | Hyaluronidase 2 | [34,60] | |
| IDO1 | Indoleamine 2,3-dioxygenase 1 | [61,62] | [62,63] |
| KDM6A | Lysine demethylase 6A | [27,56] | |
| MAP4K1 | Mitogen-activated protein kinase kinase kinase kinase 1 | [34,64] | |
| MKI67 | Marker of proliferation Ki-67 | [65,66] | |
| NFE2L2 | NFE2 like bZIP transcription factor 2 | [56,67] | |
| PIK3CA | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | [27,37,39,68] | [29,30,69] |
| RB1 | RB transcriptional corepressor 1 | [39,56] | |
| SPOCD1 | SPOC domain containing 1 | [34] | |
| STAG2 | Stromal Antigen 2 | [70,71] | |
| TERT | Telomerase reverse transcriptase | [27,72] | [73] |
| TP53 | Tumor protein p53 | [27,37,38,39,74] | [45,74] |
| VEGFA | Vascular endothelial growth factor A | [54,75] | [53] |